United Therapeutics Net Income decreased by 24.5% to $274.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 14.7%, from $322.20M to $274.90M. Over 4 years (FY 2021 to FY 2025), Net Income shows an upward trend with a 29.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates higher profitability and operational success, while a decrease may signal rising costs or declining sales.
Net income represents the total profit of the company after all operating expenses, taxes, and interest have been deduct...
Standard across all public companies, though margins vary significantly by industry sector.
net_income_cf| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $172.60M | $162.70M | $112.20M | $239.90M | $116.00M | $239.30M | $132.10M | $240.90M | $259.20M | $267.60M | $217.10M | $306.60M | $278.10M | $309.10M | $301.30M | $322.20M | $309.50M | $338.70M | $364.30M | $274.90M |
| QoQ Change | — | -5.7% | -31.0% | +113.8% | -51.6% | +106.3% | -44.8% | +82.4% | +7.6% | +3.2% | -18.9% | +41.2% | -9.3% | +11.1% | -2.5% | +6.9% | -3.9% | +9.4% | +7.6% | -24.5% |
| YoY Change | — | — | — | — | -32.8% | +47.1% | +17.7% | +0.4% | +123.4% | +11.8% | +64.3% | +27.3% | +7.3% | +15.5% | +38.8% | +5.1% | +11.3% | +9.6% | +20.9% | -14.7% |